



DOC to expand market reach with signed strategic acquisition of Muscoril® from Sanofi

Milan, Italy -April 24, 2024- DOC, a leading Italian pharmaceutical company, today announced the successful signing of an agreement to acquire Muscoril®, an iconic muscle relaxant brand in Italy, Portugal, and the Czech Republic, from Sanofi.

The transaction, which has been supported by DOC shareholders, TPG and ICG, will continue to add to DOC's offering and growth and will create a strong foundation for future expansion. Muscoril® will significantly enrich DOC's existing product line, which already boasts an extensive portfolio of over 250 molecules across multiple therapeutic areas. Consummation of the transaction is subject to customary closing conditions.



Riccardo Zagaria, CEO of DOC remarked: *“This signed acquisition is a transformative step for DOC as we continue to expand our presence in the Italian market. Muscoril® not only strengthens our existing portfolio but also complements our strategic focus on growing both our branded and generics businesses. This is aligned with our vision to build upon a scaled and resilient platform capable of driving sustainable growth”.*

Karthic Jayaraman, Partner at TPG, commented: *“The signed acquisition of Muscoril® is a testament to DOC’s ability to identify valuable assets and build an integrated platform that is enhancing care through access to important, high-quality treatments. The transaction will strengthen DOC’s position as a trusted partner to physicians, pharmacists, and patients, and we are proud to support the company in its continued expansion”.*



The agreement includes the transfer of brands, inventory, marketing authorizations and regulatory dossiers in Italy, Portugal and the Czech Republic. The acquisition does not involve the transfer of any manufacturing technology, as all production will be handled by contract manufacturing organisations (CMOs).

Muscoril®'s long-standing reputation for efficacy and patient preference has established it as one of the leading muscle relaxant brands in Italy. The brand is available in a variety of dosage forms, including orodispersible tablets, capsules and injectable solutions, providing patients with multiple treatment options.

This strategic move will strengthen DOC's market position, reinforcing the company's commitment to improving healthcare through effective and accessible treatments.

DOC is an Italian pharmaceutical company active in the branded retail and generics markets. It is the second largest player in the Italian generics market.



DOC's portfolio comprises over 250 molecules and approximately 700 SKUs covering all major therapeutic areas. DOC supplies a well-diversified range of reimbursable and non-reimbursable products to wholesalers and pharmacies in all Italian regions.

For more information, visit www.docgenerici.it

About TPG:

TPG is a leading global alternative asset management firm, founded in San Francisco in 1992, with \$222 billion of assets under management and investment and operational teams around the world. TPG invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, and market solutions, and our unique strategy is driven by collaboration, innovation and inclusion. Our teams combine deep product and sector experience with broad capabilities and expertise to develop differentiated insights and add value for our fund investors, portfolio companies, management teams, and communities. For more information, visit www.tpg.com

About ICG:

ICG provides flexible capital solutions to help companies develop and grow. ICG is a leading global alternative asset manager with over 35 years' history, managing \$86bn of assets and investing across the capital structure. ICG operates across four asset classes: Structured and Private Equity, Private Debt, Real Assets, and Credit. ICG develops long-term relationships with its business partners to deliver value for shareholders, clients and employees, and uses its position of influence to benefit the environment and society. ICG is a member of the FTSE 100 and listed on the London Stock Exchange. Further details are available at www.icgam.com.

French and Italian advisory teams took part in the Transaction.

DOC has been assisted by **Bird & Bird** - Milano, with Alberto Salvadè and Maurizio Pinto for all corporate matters, **Latham Watkins** -Milano with Erika Brini Raimondi and Pasquale Spiezio for financing aspects and **PedersoliGattai** with Cristiano Garbarini and Alban Zaimaj as tax advisor.

Sanofi has been assisted by **Jones Day** – Paris and Milano, with Gaël Saint-Olive, Stefano Crosio and Edoardo Coro for Legal advice, and **Lazard Frères** – Paris, with Guillaume Molinier and Guillaume de Fréminet, as financial advisors.

Brand Communication Manager DOC:

Sabrina D'Aiello – sabrina.daiello@genericidoc.it

Press office:

Elena Talpo – elena.talpo@mccannhealthboot.com | +39 3453165340

Greta Ammendola – greta.ammendola@mccannhealthboot.com | +39 342 6166570